Published in Curr Diab Rep on February 01, 2008
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest (2009) 2.53
Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes (2009) 1.31
Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis (2013) 1.29
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci (2015) 1.25
Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. Eur J Nutr (2012) 1.07
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease. Diabetes Metab J (2012) 1.00
Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care (2012) 0.99
Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications. Rev Diabet Stud (2012) 0.93
Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. Diabetes Care (2009) 0.93
Diabetes-induced hepatic pathogenic damage, inflammation, oxidative stress, and insulin resistance was exacerbated in zinc deficient mouse model. PLoS One (2012) 0.92
Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients (2014) 0.92
Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study. Arterioscler Thromb Vasc Biol (2012) 0.91
Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc (2013) 0.88
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab (2011) 0.86
Angiotensin receptor blockade recovers hepatic UCP2 expression and aconitase and SDH activities and ameliorates hepatic oxidative damage in insulin resistant rats. Endocrinology (2012) 0.85
Protection from Metabolic Dysregulation, Obesity, and Atherosclerosis by Citrus Flavonoids: Activation of Hepatic PGC1α-Mediated Fatty Acid Oxidation. PPAR Res (2012) 0.85
Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study. Arterioscler Thromb Vasc Biol (2015) 0.83
Expression of ceramide-metabolising enzymes in subcutaneous and intra-abdominal human adipose tissue. Lipids Health Dis (2012) 0.80
γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study. Diabetologia (2015) 0.79
The eSS rat, a nonobese model of disordered glucose and lipid metabolism and fatty liver. Diabetol Metab Syndr (2010) 0.79
Amount of hepatic fat predicts cardiovascular risk independent of insulin resistance among Hispanic-American adolescents. Lipids Health Dis (2015) 0.79
Leucine alters hepatic glucose/lipid homeostasis via the myostatin-AMP-activated protein kinase pathway - potential implications for nonalcoholic fatty liver disease. Clin Epigenetics (2014) 0.77
Freshwater Clam Extract Ameliorates Triglyceride and Cholesterol Metabolism through the Expression of Genes Involved in Hepatic Lipogenesis and Cholesterol Degradation in Rats. Evid Based Complement Alternat Med (2013) 0.77
Featured Article: Oxidative stress status and liver tissue defenses in diabetic rats during intensive subcutaneous insulin therapy. Exp Biol Med (Maywood) (2015) 0.76
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation (2007) 4.62
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes (2008) 4.20
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature (2002) 3.80
SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. Nat Cell Biol (2007) 3.69
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes (2005) 2.99
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol (2008) 2.96
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 2.90
Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet (2004) 2.86
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology (2015) 2.81
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care (2008) 2.73
The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res (2009) 2.59
Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science (2004) 2.38
Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care (2005) 2.26
[ESC/EAS Guidelines for the management of dyslipidaemias]. Rev Esp Cardiol (2011) 2.21
Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2010) 2.03
Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet (2012) 1.97
Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol (2011) 1.78
An immune response network associated with blood lipid levels. PLoS Genet (2010) 1.74
PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis (2012) 1.70
PLD1 and ERK2 regulate cytosolic lipid droplet formation. J Cell Sci (2006) 1.67
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol (2003) 1.65
Effects of a Mediterranean-inspired diet on blood lipids, vascular function and oxidative stress in healthy subjects. Clin Sci (Lond) (2004) 1.63
Cytosolic lipid droplets increase in size by microtubule-dependent complex formation. Arterioscler Thromb Vasc Biol (2005) 1.62
Lipid droplets as dynamic organelles connecting storage and efflux of lipids. Biochim Biophys Acta (2008) 1.60
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care (2011) 1.53
Retracted The SNARE protein SNAP23 and the SNARE-interacting protein Munc18c in human skeletal muscle are implicated in insulin resistance/type 2 diabetes. Diabetes (2010) 1.51
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 1.51
Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2005) 1.50
Postnatal constriction, ATP depletion, and cell death in the mature and immature ductus arteriosus. Am J Physiol Regul Integr Comp Physiol (2005) 1.49
Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish families. Am J Hum Genet (2002) 1.45
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis (2005) 1.44
Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy. Atherosclerosis (2011) 1.42
Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development. Proc Natl Acad Sci U S A (2007) 1.41
Hypoxia converts human macrophages into triglyceride-loaded foam cells. Arterioscler Thromb Vasc Biol (2006) 1.40
SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J (2010) 1.40
Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis (2003) 1.39
Adipocyte differentiation-related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low-density lipoproteins. Arterioscler Thromb Vasc Biol (2006) 1.38
High-throughput shotgun lipidomics by quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.37
The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction. J Clin Invest (2011) 1.36
PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol (2010) 1.34
Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol (2002) 1.33
Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. J Med Genet (2013) 1.26
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation (2003) 1.26
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol (2008) 1.26
Cross-species analyses implicate Lipin 1 involvement in human glucose metabolism. Hum Mol Genet (2005) 1.25
Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res (2007) 1.24
Use of genome-wide expression data to mine the "Gray Zone" of GWA studies leads to novel candidate obesity genes. PLoS Genet (2010) 1.24
Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol (2012) 1.22
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care (2010) 1.21
Diabetic dyslipidaemia. Curr Opin Lipidol (2006) 1.20
Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol (2009) 1.19
Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q. Am J Hum Genet (2003) 1.19
APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res (2004) 1.16
USF1 and dyslipidemias: converging evidence for a functional intronic variant. Hum Mol Genet (2005) 1.16
Triglyceride containing lipid droplets and lipid droplet-associated proteins. Curr Opin Lipidol (2008) 1.16
Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ Res (2008) 1.15
Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag (2007) 1.15
Common hepatic nuclear factor-4alpha variants are associated with high serum lipid levels and the metabolic syndrome. Diabetes (2006) 1.15
Statins are diabetogenic--myth or reality? Atheroscler Suppl (2012) 1.15
Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum Mol Genet (2011) 1.13
Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol (2004) 1.12
ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes (2009) 1.12
Retention of low-density lipoprotein in atherosclerotic lesions of the mouse: evidence for a role of lipoprotein lipase. Circ Res (2007) 1.11
Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation (2002) 1.11
Novel rat model reveals important roles of β-adrenoreceptors in stress-induced cardiomyopathy. Int J Cardiol (2013) 1.11
A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res (2004) 1.11
Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J Lipid Res (2010) 1.10
Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage and resistance to diet-induced obesity. FASEB J (2010) 1.10
A phospholipase D-dependent process forms lipid droplets containing caveolin, adipocyte differentiation-related protein, and vimentin in a cell-free system. J Biol Chem (2003) 1.09
ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis (2006) 1.09
One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis (2010) 1.07
Cardiac steatosis associates with visceral obesity in nondiabetic obese men. J Clin Endocrinol Metab (2013) 1.07
Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol (2006) 1.07
WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels. Am J Hum Genet (2008) 1.06
Filamins in cardiovascular development. Trends Cardiovasc Med (2007) 1.06
PARP1 is required for adhesion molecule expression in atherogenesis. Cardiovasc Res (2007) 1.06
Atherosclerotic mice exhibit systemic inflammation in periadventitial and visceral adipose tissue, liver, and pancreatic islets. Atherosclerosis (2009) 1.06
Filamin a mediates HGF/c-MET signaling in tumor cell migration. Int J Cancer (2011) 1.05
Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem (2002) 1.04
Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care (2009) 1.02
OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism. J Mol Med (Berl) (2009) 1.02
Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One (2012) 1.02
Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab (2007) 1.02